조직 진단 시장 : 예측(2025-2030년)

The tissue diagnostics market is expected to grow from USD 6.929 billion in 2025 to USD 9.409 billion in 2030, at a CAGR of 6.31%.

Rising Prevalence of Chronic Diseases

The increasing incidence of chronic diseases, particularly cancer, is a primary driver of the tissue diagnostics market. In 2024, the World Health Organization reported that chronic diseases accounted for 74% of global deaths, with cancer being a leading cause. Tissue diagnostics, encompassing techniques like immunohistochemistry (IHC), in situ hybridization (ISH), and digital pathology, are critical for accurate diagnosis and personalized treatment planning. These tools enable detailed analysis of tissue abnormalities, supporting tailored therapies for conditions like breast and lung cancer, driving demand for advanced diagnostic solutions.

Growing Geriatric Population

The global aging population is significantly boosting market growth. In 2024, the proportion of individuals aged 60 and older continued to rise, particularly in developed regions, increasing susceptibility to cancers and other chronic conditions. This demographic shift has heightened the need for tissue diagnostics to facilitate early detection and treatment, especially in oncology, where precise diagnostics are essential for improving patient outcomes.

Favorable Government Initiatives

Governments worldwide are promoting tissue diagnostics through supportive policies and funding. In 2023, the European Union allocated grants to advance precision medicine, emphasizing tissue-based diagnostics for cancer screening. Similarly, U.S. initiatives under the National Cancer Institute in 2024 supported research into advanced diagnostic technologies, fostering adoption and innovation in the market.

Diagnostic Innovations

Technological advancements are transforming tissue diagnostics. In 2023, Roche's DISCOVERY ULTRA system gained traction for its ability to automate IHC and ISH assays, enabling simultaneous manual and automated experiments with 30 independent slide drawers. This system supports complex assays like FISH and multiplex protein IHC/ISH, enhancing diagnostic accuracy. Such innovations streamline workflows in hospitals and laboratories, meeting the growing demand for rapid, precise diagnostics.

High Hospital Adoption

Hospitals are increasingly adopting tissue-based diagnostic solutions due to their speed and accuracy compared to conventional methods. In 2024, the rising burden of chronic diseases, particularly cancer, drove hospital demand for tissue diagnostics. These solutions enable faster diagnosis, critical for conditions requiring immediate intervention, such as oncology and cardiovascular diseases, further propelling market growth.

Market Restraints

High Costs

The high cost of advanced tissue diagnostic instruments and reagents limits adoption, particularly in developing regions. In 2024, the cost of automated systems like digital pathology platforms remained a barrier for smaller healthcare facilities, despite their efficiency.

Regulatory Complexity

Diverse regulatory frameworks across regions pose challenges. In 2023, stringent approval processes in the EU delayed the rollout of new diagnostic tools, increasing compliance costs for manufacturers and slowing market expansion.

Technical Expertise Requirements

The effective use of advanced tissue diagnostics requires specialized training, which is often limited in developing regions. In 2024, this gap hindered adoption in parts of Asia-Pacific and Africa, where healthcare infrastructure is still evolving.

Market Segmentation Analysis

By Technology

Immunohistochemistry (IHC) dominates due to its widespread use in cancer diagnostics. In 2024, IHC accounted for over 40% of market revenue, driven by its precision in detecting molecular markers. Digital pathology is the fastest-growing segment, fueled by AI integration for enhanced image analysis.

By Application

Cancer diagnosis leads, with tissue diagnostics critical for identifying tumor types and guiding targeted therapies. Other applications, like infectious and autoimmune disease diagnostics, are growing steadily due to rising disease prevalence.

By End-User

Hospitals hold the largest share, driven by high adoption of tissue diagnostics for rapid and accurate testing. Diagnostic laboratories are expanding, supported by outsourcing trends in 2024.

Geographical Insights

North America, led by the U.S., dominates the market, holding a 38% share in 2024, driven by advanced healthcare infrastructure and a high cancer burden. Europe follows, with Germany and the UK leading due to strong focus on early diagnosis and screening programs. Asia-Pacific is the fastest-growing region, with China and India investing heavily in diagnostic infrastructure in 2023 to address rising chronic disease rates.

Competitive Landscape

Key players, including Roche, Abbott Laboratories, Agilent Technologies, BD, and Cardinal Health, drive innovation. In 2023, Roche enhanced its portfolio with automated IHC systems, while Agilent introduced AI-integrated digital pathology solutions in 2024. These companies leverage R&D and strategic partnerships to maintain market leadership.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Market Segmentation:

By Product

• Consumables
• Antibodies
• Kits
• Probes
• Reagents
• Instruments
• Slide Scanners
• Slide Staining Systems
• Tissue Microarrays
• Tissue Processing Systems
• Others

By Technology

• Digital Pathology
• Immunohistochemistry (IHC)
• In Situ Hybridization (ISH)
• Others

By Application

• Breast cancer
• Cervical cancer
• Colorectal cancer
• Gastric cancer
• Lung cancer
• Others

By End-Users

• Contract Research Organizations (CROs)
• Hospitals
• Diagnostic Centers
• Others

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Others
• Middle East and Africa
• UAE
• Saudi Arabia
• Others
• Asia Pacific
• Japan
• China
• South Korea
• India
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. TISSUE DIAGNOSTICS MARKET BY PRODUCT

• 5.1. Introduction
• 5.2. Consumables
  • 5.2.1. Antibodies
  • 5.2.2. Kits
  • 5.2.3. Probes
  • 5.2.4. Reagents
• 5.3. Instruments
  • 5.3.1. Slide Scanners
  • 5.3.2. Slide Staining System
  • 5.3.3. Tissue Microarrays
  • 5.3.4. Tissue Processing System
  • 5.3.5. Others

6. TISSUE DIAGNOSTICS MARKET BY TECHNOLOGY

• 6.1. Introduction
• 6.2. Digital Pathology
• 6.3. Immunohistochemistry (IHC)
• 6.4. In Situ Hybridization (ISH)
• 6.5. Others

7. TISSUE DIAGNOSTICS MARKET BY APPLICATION

• 7.1. Introduction
• 7.2. Breast Cancer
• 7.3. Cervical Cancer
• 7.4. Colorectal Cancer
• 7.5. Gastric Cancer
• 7.6. Lung Cancer
• 7.7. Others

8. TISSUE DIAGNOSTICS MARKET BY END-USER

• 8.1. Introduction
• 8.2. Contract Research Organization (CRO)
• 8.3. Hospitals
• 8.4. Diagnostics Centers
• 8.5. Others

9. TISSUE DIAGNOSTICS MARKET BY GEOGRAPHY

• 9.1. Introduction
• 9.2. North America
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End-User
  • 9.2.5. By Country
    • 9.2.5.1. USA
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. South America
  • 9.3.1. By Product
  • 9.3.2. By Technology
  • 9.3.3. By Application
  • 9.3.4. By End-User
  • 9.3.5. By Country
    • 9.3.5.1. Brazil
    • 9.3.5.2. Argentina
    • 9.3.5.3. Others
• 9.4. Europe
  • 9.4.1. By Product
  • 9.4.2. By Technology
  • 9.4.3. By Application
  • 9.4.4. By End-User
  • 9.4.5. By Country
    • 9.4.5.1. Germany
    • 9.4.5.2. France
    • 9.4.5.3. United Kingdom
    • 9.4.5.4. Spain
    • 9.4.5.5. Others
• 9.5. Middle East and Africa
  • 9.5.1. By Product
  • 9.5.2. By Technology
  • 9.5.3. By Application
  • 9.5.4. By End-User
  • 9.5.5. By Country
    • 9.5.5.1. Saudi Arabia
    • 9.5.5.2. UAE
    • 9.5.5.3. Others
• 9.6. Asia Pacific
  • 9.6.1. By Product
  • 9.6.2. By Technology
  • 9.6.3. By Application
  • 9.6.4. By End-User
  • 9.6.5. By Country
    • 9.6.5.1. China
    • 9.6.5.2. India
    • 9.6.5.3. Japan
    • 9.6.5.4. South Korea
    • 9.6.5.5. Indonesia
    • 9.6.5.6. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Market Share Analysis
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Competitive Dashboard

11. COMPANY PROFILES

• 11.1. Abbott Laboratories
• 11.2. Agilent Technologies, Inc.
• 11.3. Becton Dickinson
• 11.4. BioGenex
• 11.5. Cardinal Health
• 11.6. Danaher
• 11.7. F. Hoffmann-La Roche Ltd
• 11.8. Medtronic
• 11.9. Merck KgaA
• 11.10. Thermo Fisher Scientific Inc.

12. APPENDIX

• 12.1. Currency
• 12.2. Assumptions
• 12.3. Base and Forecast Years Timeline
• 12.4. Key benefits for the stakeholders
• 12.5. Research Methodology
• 12.6. Abbreviations